Neximmune Stock Cash Flow From Operations
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Neximmune's long-term financial health and intrinsic value.
Neximmune |
Neximmune Company Cash Flow From Operations Analysis
Neximmune's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Neximmune Cash Flow From Operations | (31.43 M) |
Most of Neximmune's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neximmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Neximmune has (31.43 Million) in Cash Flow From Operations. This is 105.96% lower than that of the Biotechnology sector and 150.27% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 103.24% higher than that of the company.
Neximmune Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neximmune's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Neximmune could also be used in its relative valuation, which is a method of valuing Neximmune by comparing valuation metrics of similar companies.Neximmune is currently under evaluation in cash flow from operations category among its peers.
Neximmune Fundamentals
| Return On Equity | -1.96 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | (491.95 K) | ||||
| Shares Outstanding | 1.37 M | ||||
| Shares Owned By Insiders | 17.00 % | ||||
| Shares Owned By Institutions | 11.17 % | ||||
| Number Of Shares Shorted | 15.99 K | ||||
| Price To Book | 1.38 X | ||||
| EBITDA | (28.17 M) | ||||
| Net Income | (32.34 M) | ||||
| Cash And Equivalents | 53.13 M | ||||
| Cash Per Share | 2.20 X | ||||
| Total Debt | 68.81 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 6.54 X | ||||
| Book Value Per Share | 2.00 X | ||||
| Cash Flow From Operations | (31.43 M) | ||||
| Short Ratio | 2.26 X | ||||
| Earnings Per Share | (24.11) X | ||||
| Target Price | 2.0 | ||||
| Beta | 1.94 | ||||
| Market Capitalization | 3.25 M | ||||
| Total Asset | 8.59 M | ||||
| Retained Earnings | (222.59 M) | ||||
| Working Capital | 316.73 K | ||||
| Net Asset | 8.59 M |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Neximmune Pink Sheet
If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |